Sign In
Buy KYMR
$73.21
+1.92 (+2.69%)
At Close: Jun 03, 2026
Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Misses Revenue Estimates
09:11am, Tuesday, 04'th Nov 2025
Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.9 per share versus the Zacks Consensus Estimate of a loss of $0.71. This compares to a loss of $0.82 per share a year ago.
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
07:00am, Monday, 03'rd Nov 2025
WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines
Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025
07:00am, Tuesday, 28'th Oct 2025
WATERTOWN, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines
KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid arthritis (RA), with activity comparable or superior to appro
Kymera Therapeutics, Inc. (KYMR) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
11:00am, Thursday, 23'rd Oct 2025
Kymera Therapeutics (KYMR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline
10:42am, Wednesday, 01'st Oct 2025
Kymera advances its protein degradation pipeline with new Sanofi and Gilead deals, milestone payouts, and promising trial updates.
Kymera Therapeutics, Inc. (KYMR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
04:42pm, Tuesday, 09'th Sep 2025
Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 12:20 PM EDT Company Participants Nello Mainolfi - Co-Founder, President, CEO & Direc
Kymera Therapeutics, Inc. (KYMR) Presents At Citi's 2025 Biopharma Back To School Conference Transcript
01:31pm, Wednesday, 03'rd Sep 2025
Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Citi's 2025 Biopharma Back to School Conference September 3, 2025 10:30 AM EDT Company Participants Nello Mainolfi - Co-Founder, President, CEO & Director Jare
Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary
07:00am, Wednesday, 03'rd Sep 2025
WATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicine
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
07:00am, Wednesday, 27'th Aug 2025
WATERTOWN, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines
Kymera Therapeutics, Inc. (KYMR) Q2 2025 Earnings Call Transcript
01:25pm, Monday, 11'th Aug 2025
Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q2 2025 Earnings Conference Call August 11, 2025 8:30 AM ET Company Participants Bruce N. Jacobs - Chief Financial Officer Jared A.
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Misses Revenue Estimates
09:11am, Monday, 11'th Aug 2025
Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to a loss of $0.58 per share a year ago.
Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update
07:00am, Monday, 11'th Aug 2025
Reported positive KT-621 (STAT6) Phase 1 healthy volunteer data surpassing Kymera's target product profile, and further validating its oral, dupilumab-like profile
Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
11:06am, Wednesday, 30'th Jul 2025
Kymera Therapeutics (KYMR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock?
10:56am, Friday, 18'th Jul 2025
KYMR jumps 70.7% in 3 months as the $750M oncology deal with GILD and pipeline advances in TPD drugs impress investors.
